2022 Archives - Alpha-9 Oncology

Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer

Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement

Alpha-9 Starts Construction of Research Facility in Vancouver

Isotopia Molecular Imaging and Alpha-9 Theranostics Announce Lutetium-177 Supply Agreement

Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials